Contents
THE EUROPEAN COMMISSION,Having regard to the Treaty on the Functioning of the European Union,Having regard to Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Councilnote, and in particular Article 14, in conjunction with Article 17, thereof,Whereas:
(1)Table 1 of the Annex to Commission Regulation (EU) No 37/2010note sets out the pharmacologically active substances and their classification regarding maximum residue limits (‘MRLs’) in foodstuffs of animal origin.
(2)The substance sodium salicylate is included in that table as an allowed substance.
(3)On 30 September 2022, pursuant to Article 3 of Regulation (EC) No 470/2009, Dopharma B.V. submitted an application to the European Medicines Agency (‘Agency’) for the extension of the existing entry for the substance sodium salicylate to chicken.
(4)On 5 October 2023, the Agency, based on the opinion of the Committee for Veterinary Medicinal Products, set up pursuant to Article 139 of Regulation (EU) 2019/6 of the European Parliament and of the Councilnote, and having considered the application of Dopharma B.V., recommended the extension of maximum residue limits for the substance sodium salicylate in chicken and the establishment of numerical MRLs.
(5)The Agency also concluded that the extrapolation of the MRLs for sodium salicylate from chicken tissues to the tissues of other poultry species other than turkey is appropriate.
(6)In view of the opinion of the Agency, the Commission considers it appropriate to establish the recommended MRL for sodium salicylate in chicken tissues and to extrapolate it to other poultry species other than turkey, but restricted to animals not producing eggs for human consumption as no residue data were provided for eggs.
(7)Regulation (EU) No 37/2010 should therefore be amended accordingly.
(8)The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,
HAS ADOPTED THIS REGULATION:
Article 1#
The Annex to Regulation (EU) No 37/2010 is amended as set out in the Annex to this Regulation.
Article 2#
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
In Table 1 of the Annex to Regulation (EU) No 37/2010, the entry for the pharmacologically active substance ‘sodium salicylate’ is replaced by the following:
Pharmacologically active Substance | Marker residue | Animal Species | MRL | Target Tissues | Other Provisions(according to Article 14(7) of Regulation (EC) No 470/2009) | Therapeutic ClassificationSodium salicylate | NOT APPLICABLE | Bovine, Porcine | No MRL required | NOT APPLICABLE | For oral use.Not for use in animals from which milk is produced for human consumption. | NO ENTRYAll food producing species except fin fish | No MRL required | For topical use only.Salicylic acid | Turkey | 400 μg/kg2500 μg/kg200 μg/kg150 μg/kg | MuscleSkin and fat in natural proportionsLiverKidney | Not for use in animals producing eggs for human consumption. | Anti-inflammatory agents / Non-steroidal anti-inflammatory agents.Poultry other than turkey | 250 μg/kg250 μg/kg500 μg/kg1000 μg/kg | MuscleSkin and fat in natural proportionsLiverKidney
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.